Acute HIV, and the Case for Starting Before the Ink Is Dry
Every day of delay plausibly lets the viral reservoir seed further and gives him more time to disengage from care before treatment starts — the counterargument is that treating blind, before knowing his resistance profile, carries its own real cost.
K.R., a 26-year-old man, lives with his older brother and has spent the past year training seriously for his first half-marathon, a goal that made the last ten days feel especially wrong — a fever, drenching night sweats, a sore throat, and a faint rash across his trunk that he initially assumed was a reaction to new laundry detergent. He works as a barista, a job with a schedule flexible enough that he almost talked himself out of coming in at all. A friend who'd gone through something similar a few years earlier suggested he get tested rather than wait it out, and a fourth-generation antigen/antibody test today came back reactive, with a follow-up differentiation assay pattern consistent with acute, very recent infection rather than an established one. He reports a single new sexual partner about three weeks ago and no prior HIV testing history. He says he'd assumed the fatigue was simply overtraining, and only came in at all because the rash was new and unexplained.
His presentation — fever, pharyngitis, rash, and lymphadenopathy roughly two to four weeks after a plausible exposure — is close to a textbook description of acute retroviral seroconversion illness, and his lab pattern places him in an early Fiebig stage, before a fully mature antibody response has developed. Confirmatory testing and a baseline resistance genotype have both been sent but won't return for several days. The question in front of the team is whether to start ART today, on the strength of the clinical picture and the reactive screening result alone, or wait for those results to return first. San Francisco's RAPID program, which offers same-day ART initiation after a positive test, found faster suppression and better retention in care compared with a delayed-start approach, and the Thai RV254/SEARCH010 cohort, which specifically studies patients treated during these earliest Fiebig stages, has found evidence that very early treatment measurably limits how large and how genetically diverse the latent reservoir becomes before it's ever brought under control. His own two dates are what place him inside that cohort rather than merely near it: a single exposure about three weeks ago and ten days of symptoms put his seroconversion illness roughly eleven days after transmission, early enough that his antibody response has not finished maturing, which is precisely the window RV254 recruited into and reported its smallest reservoirs from. The reservoir-limiting argument is not a general claim about treating early that happens to include him; it is a claim about the fortnight he is currently standing in.
Urgent care clinic, same-day rapid-test-positive visit
His clinical picture and lab pattern both point to very early acute infection, and that's specifically when starting matters most. RAPID's same-day-initiation protocol showed faster suppression and better retention in care than waiting, and RV254's cohort data suggests treating this early measurably limits how large and diverse his viral reservoir becomes before it's controlled — and the benefit in that cohort wasn't flat across the acute window, it was concentrated in the earliest Fiebig stages, which is exactly where his differentiation-assay pattern places him. A week or two later and I'd still argue for early treatment, just with less confidence that the reservoir-size argument is doing real work rather than theoretical work. I'd start ART today rather than wait several days for results that won't change the overall recommendation to treat.
I'm not disputing that early treatment has real reservoir and retention benefits.
My concern is narrower: we're about to start him on a regimen with zero information about his actual resistance profile. Transmitted resistance is uncommon but not zero, and starting a regimen he may already be partially resistant to risks both inadequate suppression and adding resistance mutations on top of whatever he may have acquired. A few days isn't a large cost against getting that information first. If we do start today, I'd want the NRTI backbone chosen with an eye to what we don't yet know — his renal function is normal now, but he's about to be on this regimen for years, and tenofovir alafenamide's lower circulating tenofovir concentration gives us more room than the older disoproxil formulation if anything changes down the line.
I think there's a way to get both benefits without the tradeoff either of you is describing. A high-genetic-barrier integrase-inhibitor-based regimen — bictegravir with tenofovir alafenamide and emtricitabine — remains effective against essentially all plausible transmitted-resistance patterns, which resolves the pharmacologist's concern structurally rather than by waiting for the result. Start it today, and simply adjust if the genotype comes back showing something genuinely unusual.
Agreed: ART started today, using a regimen chosen specifically to remain effective regardless of what the pending resistance genotype eventually shows — resolving the pharmacologist's concern through drug selection rather than through delay. Genotype and confirmatory results will be reviewed at his one-week follow-up, with the regimen adjusted only if something genuinely unexpected turns up.